• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.HLA 单倍体相合与同胞相合造血细胞移植：系统评价和荟萃分析。
Blood Adv. 2019 Sep 10;3(17):2581-2585. doi: 10.1182/bloodadvances.2019000614.
2
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.单倍体相合与同胞相合移植治疗急性髓系白血病完全缓解 1 期的结果。
Blood Adv. 2019 Jun 25;3(12):1826-1836. doi: 10.1182/bloodadvances.2019000050.
3
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.使用单倍体相合相关供者与人类白细胞抗原（HLA）匹配的同胞供者进行淋巴瘤的减低强度移植：国际血液和骨髓移植研究中心分析
J Clin Oncol. 2016 Sep 10;34(26):3141-9. doi: 10.1200/JCO.2015.66.3476. Epub 2016 Jun 6.
4
Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.来自半相合供体与基因相合同胞供体的造血干细胞移植治疗成人男性急性髓系白血病患者首次完全缓解：来自欧洲血液和骨髓移植学会急性白血病工作组的一项回顾性研究。
Cancer. 2020 Mar 1;126(5):1004-1015. doi: 10.1002/cncr.32629. Epub 2019 Nov 27.
5
Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations.单倍体相合与 HLA 匹配的同胞供者造血干细胞移植加 PTCy 预防：HLA 因素和供者年龄的考虑。
Blood Adv. 2024 Oct 22;8(20):5306-5314. doi: 10.1182/bloodadvances.2024013853.
6
T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.采用移植后环磷酰胺的T细胞充足的外周血单倍体相合造血细胞移植，在活动性疾病急性髓系白血病中产生的结果与来自传统匹配供体的移植相似。
Biol Blood Marrow Transplant. 2017 Apr;23(4):648-653. doi: 10.1016/j.bbmt.2017.01.068. Epub 2017 Jan 10.
7
Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes.人类白细胞抗原纯合单倍型患者的单倍型相合及全相合同胞供者造血细胞移植
Biol Blood Marrow Transplant. 2016 Nov;22(11):2031-2037. doi: 10.1016/j.bbmt.2016.07.020. Epub 2016 Aug 1.
8
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.急性髓系白血病患者接受同胞供者、无关供者和单倍体相合供者移植后应用环磷酰胺：ALWP EBMT 的比较研究。
J Hematol Oncol. 2020 May 6;13(1):46. doi: 10.1186/s13045-020-00882-6.
9
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.使用白消安、氟达拉滨和抗胸腺细胞球蛋白进行减低强度预处理用于缓解期急性髓系白血病患者接受无关或单倍体相合家庭供者造血细胞移植
Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. doi: 10.1016/j.bbmt.2017.05.025. Epub 2017 May 25.
10
Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.采用 HLA 单倍体相合供者进行外周血造血干细胞移植并于移植后使用环磷酰胺与 HLA 同胞相合供者进行淋巴瘤移植的比较。
Bone Marrow Transplant. 2024 May;59(5):630-636. doi: 10.1038/s41409-024-02229-y. Epub 2024 Feb 14.

引用本文的文献

1
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies.老年血液系统恶性肿瘤患者的异基因造血干细胞移植
Yonago Acta Med. 2025 Jul 17;68(3):169-179. doi: 10.33160/yam.2025.08.001. eCollection 2025 Aug.
2
Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors-A Single Center Experience in 152 Patients.单倍体相合异基因干细胞移植作为供者不相合患者的一种更优选择——152例患者的单中心经验
EJHaem. 2025 Mar 4;6(2):e70012. doi: 10.1002/jha2.70012. eCollection 2025 Apr.
3
Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.急性髓系白血病中来自替代供者的异基因造血细胞移植。
Ann Hematol. 2024 Dec;103(12):4851-4868. doi: 10.1007/s00277-024-05944-0. Epub 2024 Aug 17.
4
The health risk of social disadvantage is transplantable into a new host.社会劣势的健康风险是可移植到新宿主的。
Proc Natl Acad Sci U S A. 2024 Jul 23;121(30):e2404108121. doi: 10.1073/pnas.2404108121. Epub 2024 Jul 15.
5
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.新型 MAGIC 综合评分结合临床症状和生物标志物，可更好地预测急性移植物抗宿主病的治疗效果。
Blood. 2024 Aug 29;144(9):1010-1021. doi: 10.1182/blood.2024025106.
6
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.供者类型和移植结局在骨髓纤维化中的研究：CIBMTR 研究。
Blood Adv. 2024 Aug 27;8(16):4281-4293. doi: 10.1182/bloodadvances.2024013451.
7
Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.移植后环磷酰胺为基础的异基因造血细胞移植的移植物抗肿瘤效应。
Front Immunol. 2024 Jun 6;15:1403936. doi: 10.3389/fimmu.2024.1403936. eCollection 2024.
8
Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients and Donors.根据受者和供者的免疫特征分析人类白细胞抗原匹配的相关供者及单倍体相合异基因造血细胞移植受者的结局
Transplant Cell Ther. 2024 Aug;30(8):808.e1-808.e13. doi: 10.1016/j.jtct.2024.05.018. Epub 2024 May 25.
9
Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study.中国≥55 岁急性髓系白血病或骨髓增生异常综合征患者异基因造血干细胞移植的结果：一项回顾性研究。
Stem Cell Res Ther. 2024 Jan 29;15(1):24. doi: 10.1186/s13287-024-03640-4.
10
GVHD relapse-free survival after peripheral blood hematopoietic cell transplantation for hematologic malignancies.血液系统恶性肿瘤患者外周血造血细胞移植后的移植物抗宿主病无复发生存率。
Blood Cell Ther. 2023 May 19;6(3):66-71. doi: 10.31547/bct-2022-014. eCollection 2023 Aug 25.

本文引用的文献

1
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.移植后环磷酰胺为基础的单倍体相合与同胞供者减低强度预处理移植治疗霍奇金淋巴瘤：降低移植物抗宿主病和复发风险。
Biol Blood Marrow Transplant. 2019 Sep;25(9):1859-1868. doi: 10.1016/j.bbmt.2019.05.025. Epub 2019 May 25.
2
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?年龄≥50 岁的急性髓系白血病患者的异体供者移植：年轻的 HLA 匹配的无关供者或单倍体相合供者？
Haematologica. 2020 Jan 31;105(2):407-413. doi: 10.3324/haematol.2018.215202. Print 2020.
3
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).三种预防方案（他克莫司、霉酚酸酯和环磷酰胺；他克莫司、甲氨蝶呤和硼替佐米；或他克莫司、甲氨蝶呤和马拉维若）与他克莫司和甲氨蝶呤用于预防低强度预处理造血细胞移植后的移植物抗宿主病：一项带有非随机同期对照组的随机2期试验（BMT CTN 1203）
Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.
4
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.基于 PTCy 的单倍体相合与匹配相关或无关供者减低强度预处理移植治疗弥漫性大 B 细胞淋巴瘤。
Blood Adv. 2019 Feb 12;3(3):360-369. doi: 10.1182/bloodadvances.2018027748.
5
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?亲缘供者移植：移植后环磷酰胺是否消除了 HLA 错配的有害影响？
Blood Adv. 2018 Jun 12;2(11):1180-1186. doi: 10.1182/bloodadvances.2018018291.
6
HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.HLA 匹配的同胞供者与无关供者和单倍体相合相关供者异基因造血干细胞移植治疗 60 岁以上急性髓系白血病患者：一项单中心供者比较。
Biol Blood Marrow Transplant. 2018 Jul;24(7):1449-1454. doi: 10.1016/j.bbmt.2018.02.002. Epub 2018 Feb 12.
7
Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.在接受异基因造血细胞移植的霍奇金淋巴瘤患者中，单倍体相合供者较HLA匹配的相关供者疗效更佳——法语国家骨髓移植与细胞治疗协会的一项研究
Bone Marrow Transplant. 2018 Apr;53(4):400-409. doi: 10.1038/s41409-017-0018-z. Epub 2018 Jan 12.
8
Quantifying publication bias in meta-analysis.量化荟萃分析中的发表偏倚。
Biometrics. 2018 Sep;74(3):785-794. doi: 10.1111/biom.12817. Epub 2017 Nov 15.
9
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.移植后环磷酰胺为基础的单倍体相合移植作为霍奇金淋巴瘤同胞或无关供者移植的替代方案：欧洲血液和骨髓移植学会淋巴瘤工作组的注册研究。
J Clin Oncol. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28.
10
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.动员外周血干细胞与未刺激骨髓作为移植物来源用于采用移植后环磷酰胺的T细胞充足单倍体相合供体移植
J Clin Oncol. 2017 Sep 10;35(26):3002-3009. doi: 10.1200/JCO.2017.72.8428. Epub 2017 Jun 23.

HLA 单倍体相合与同胞相合造血细胞移植：系统评价和荟萃分析。

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.

机构信息

Division of Hematology, Oncology, and Transplantation, Department of Medicine, and.

Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.

出版信息

Blood Adv. 2019 Sep 10;3(17):2581-2585. doi: 10.1182/bloodadvances.2019000614.

DOI:10.1182/bloodadvances.2019000614
PMID:31484635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6737418/
Abstract

HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

摘要

HLA 单倍体相合造血细胞移植（haplo-HCT）联合移植后环磷酰胺（PT-Cy）是在没有匹配同胞供者（MSD）时的替代策略。我们进行了系统评价和荟萃分析，以比较 MSD 与 haplo-HCT 的结果。共有 11 项研究（1410 例 haplo-HCT 和 6396 例 MSD 受者）进行了荟萃分析。所有研究均为回顾性且质量较高，其中 9 项为多中心研究。haplo-HCT 与慢性移植物抗宿主病（GVHD）的风险降低约 50%相关（风险比 [HR]，0.55；95%置信区间 [CI]，0.41-0.74），但非复发死亡率的风险升高（HR，1.36；95%CI，1.12-1.66）。两组间的复发、生存、急性 GVHD 和无 GVHD 无复发生存率无显著差异。需要进一步研究来阐明 PT-Cy 和 HLA 错配对两组间观察到的结果差异的相对贡献。